tetano
Editor, Senior Moderator
Respirology
. 2021 Nov 24.
doi: 10.1111/resp.14191. Online ahead of print.
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
Chris Ka Pun Mok[SUP] 1 2 [/SUP], Carolyn A Cohen[SUP] 3 [/SUP], Samuel M S Cheng[SUP] 4 [/SUP], Chunke Chen[SUP] 1 2 [/SUP], Kin-On Kwok[SUP] 1 [/SUP], Karen Yiu[SUP] 5 [/SUP], Tat-On Chan[SUP] 5 [/SUP], Maireid Bull[SUP] 3 [/SUP], Kwun Cheung Ling[SUP] 5 [/SUP], Zixi Dai[SUP] 3 [/SUP], Susanna S Ng[SUP] 5 [/SUP], Grace Chung-Yan Lui[SUP] 5 6 [/SUP], Chao Wu[SUP] 7 [/SUP], Gaya K Amerasinghe[SUP] 7 [/SUP], Daisy W Leung[SUP] 8 [/SUP], Samuel Yeung Shan Wong[SUP] 1 [/SUP], Sophie A Valkenburg[SUP] 3 [/SUP], Malik Peiris[SUP] 3 4 [/SUP], David S Hui[SUP] 5 6 [/SUP]
Affiliations
Abstract
Background and objective: Few head-to-head evaluations of immune responses to different vaccines have been reported.
Methods: Surrogate virus neutralization test (sVNT) antibody levels of adults receiving either two doses of BNT162b2 (n = 366) or CoronaVac (n = 360) vaccines in Hong Kong were determined. An age-matched subgroup (BNT162b2 [n = 49] vs. CoronaVac [n = 49]) was tested for plaque reduction neutralization (PRNT) and spike-binding antibody and T-cell reactivity in peripheral blood mononuclear cells.
Results: One month after the second dose of vaccine, BNT162b2 elicited significantly higher PRNT[SUB]50[/SUB] , PRNT[SUB]90[/SUB] , sVNT, spike receptor binding, spike N-terminal domain binding, spike S2 domain binding, spike FcR binding and antibody avidity levels than CoronaVac. The geometric mean PRNT[SUB]50[/SUB] titres in those vaccinated with BNT162b2 and CoronaVac vaccines were 251.6 and 69.45, while PRNT[SUB]90[/SUB] titres were 98.91 and 16.57, respectively. All of those vaccinated with BNT162b2 and 45 (91.8%) of 49 vaccinated with CoronaVac achieved the 50% protection threshold for PRNT[SUB]90.[/SUB] Allowing for an expected seven-fold waning of antibody titres over 6 months for those receiving CoronaVac, only 16.3% would meet the 50% protection threshold versus 79.6% of BNT162b2 vaccinees. Age was negatively correlated with PRNT[SUB]90[/SUB] antibody titres. Both vaccines induced SARS-CoV-2-specific CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell responses at 1 month post-vaccination but CoronaVac elicited significantly higher structural protein-specific CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell responses.
Conclusion: Vaccination with BNT162b2 induces stronger humoral responses than CoronaVac. CoronaVac induces higher CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell responses to the structural protein than BNT162b2.
Keywords: BNT162b2; Biontech; COVID-19; CoronaVac; SARS-CoV-2; Sinovac; coronavirus disease; immunogenicity.
. 2021 Nov 24.
doi: 10.1111/resp.14191. Online ahead of print.
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
Chris Ka Pun Mok[SUP] 1 2 [/SUP], Carolyn A Cohen[SUP] 3 [/SUP], Samuel M S Cheng[SUP] 4 [/SUP], Chunke Chen[SUP] 1 2 [/SUP], Kin-On Kwok[SUP] 1 [/SUP], Karen Yiu[SUP] 5 [/SUP], Tat-On Chan[SUP] 5 [/SUP], Maireid Bull[SUP] 3 [/SUP], Kwun Cheung Ling[SUP] 5 [/SUP], Zixi Dai[SUP] 3 [/SUP], Susanna S Ng[SUP] 5 [/SUP], Grace Chung-Yan Lui[SUP] 5 6 [/SUP], Chao Wu[SUP] 7 [/SUP], Gaya K Amerasinghe[SUP] 7 [/SUP], Daisy W Leung[SUP] 8 [/SUP], Samuel Yeung Shan Wong[SUP] 1 [/SUP], Sophie A Valkenburg[SUP] 3 [/SUP], Malik Peiris[SUP] 3 4 [/SUP], David S Hui[SUP] 5 6 [/SUP]
Affiliations
- PMID: 34820940
- DOI: 10.1111/resp.14191
Abstract
Background and objective: Few head-to-head evaluations of immune responses to different vaccines have been reported.
Methods: Surrogate virus neutralization test (sVNT) antibody levels of adults receiving either two doses of BNT162b2 (n = 366) or CoronaVac (n = 360) vaccines in Hong Kong were determined. An age-matched subgroup (BNT162b2 [n = 49] vs. CoronaVac [n = 49]) was tested for plaque reduction neutralization (PRNT) and spike-binding antibody and T-cell reactivity in peripheral blood mononuclear cells.
Results: One month after the second dose of vaccine, BNT162b2 elicited significantly higher PRNT[SUB]50[/SUB] , PRNT[SUB]90[/SUB] , sVNT, spike receptor binding, spike N-terminal domain binding, spike S2 domain binding, spike FcR binding and antibody avidity levels than CoronaVac. The geometric mean PRNT[SUB]50[/SUB] titres in those vaccinated with BNT162b2 and CoronaVac vaccines were 251.6 and 69.45, while PRNT[SUB]90[/SUB] titres were 98.91 and 16.57, respectively. All of those vaccinated with BNT162b2 and 45 (91.8%) of 49 vaccinated with CoronaVac achieved the 50% protection threshold for PRNT[SUB]90.[/SUB] Allowing for an expected seven-fold waning of antibody titres over 6 months for those receiving CoronaVac, only 16.3% would meet the 50% protection threshold versus 79.6% of BNT162b2 vaccinees. Age was negatively correlated with PRNT[SUB]90[/SUB] antibody titres. Both vaccines induced SARS-CoV-2-specific CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell responses at 1 month post-vaccination but CoronaVac elicited significantly higher structural protein-specific CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell responses.
Conclusion: Vaccination with BNT162b2 induces stronger humoral responses than CoronaVac. CoronaVac induces higher CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell responses to the structural protein than BNT162b2.
Keywords: BNT162b2; Biontech; COVID-19; CoronaVac; SARS-CoV-2; Sinovac; coronavirus disease; immunogenicity.